Sentinel Surveillance for Influenza Requiring Hospital Admission Canadian Adults

Conditions

Influenza

Keywords

Influenza, Respiratory Infection

Brief summary

This surveillance study will include all consenting adults hospitalized with influenza (cases) at the SOS network of hospitals as well as influenza negative patients(controls), to assess vaccine effectiveness in each group. Both groups will be followed throughout their hospitalization and for 30 days post discharge to monitor severity of illness and outcomes following their illness.

Detailed description

The Canadian Immunization Research Network(CIRN) is a collaborative research network which brings together over 100 investigators in over 40 institutions to evaluate all factors relevant to the introduction of a pandemic influenza vaccine in Canada. The Serious Outcomes Surveillance (SOS) Network within CIRN was established in 2009 to plan for evaluation of influenza vaccine safety and effectiveness. Vaccine effectiveness studies are critical in assessing vaccine effectiveness under real world conditions and in assessing vaccine effectiveness in the prevention of severe outcomes. Establishing the methodology and infrastructure for real-time field assessment of vaccine effectiveness is crucial to inform policy recommendations for the optimal use of resources, including vaccines. This study will include all consenting adult patients hospitalized at one of the SOS Network hospitals during influenza season who test positive for influenza (cases). In addition two influenza negative controls will be matched to each case to measure differences in vaccine effectiveness. Specific study aims are: 1. To determine the effectiveness of trivalent influenza vaccination (TIV in general, and GSK TIV in particular) in preventing influenza-associated hospitalization in adults ≥ 65 years, 2. To determine the effectiveness of influenza vaccination in preventing influenza-associated death in adults ≥ 65 years 3. To determine the effectiveness of influenza vaccination in preventing influenza-associated hospitalization and death in adults \< 65 years 4. To characterize the burden of disease, clinical outcomes, and resource utilization associated with influenza A and influenza B lineages 5. To examine clinical and immunologic factors impacting on severity of disease and influenza vaccine effectiveness in adults

Henrique Pott, Jason J. LeBlanc, May ElSherif, Todd F. Hatchette, Melissa K. Andrew et al. (6 authors)

The Journal of Infectious Diseases2025-07-152 citations

10.1093/infdis/jiaf083

Oseltamivir Reduces 30-Day Mortality in Older Adults With Influenza: A Pooled Analysis From the 2012–2019 Serious Outcomes Surveillance Network of the Canadian Immunization Research Network

Henrique Pott, Melissa K. Andrew, Zachary Shaffelburg, Michaela Nichols, L Ye et al. (28 authors)

Open Forum Infectious Diseases2025-01-315 citations

10.1093/ofid/ofaf058

Impact of respiratory viral infections on mortality and critical illness among hospitalized patients with chronic obstructive pulmonary disease

Sunita Mulpuru, Melissa K. Andrew, Lingyun Ye, Todd F. Hatchette, Jason J. LeBlanc et al. (12 authors)

Influenza and Other Respiratory Viruses2022-09-0717 citations

10.1111/irv.13050

Validation of the Seegene RV15 multiplex PCR for the detection of influenza A subtypes and influenza B lineages during national influenza surveillance in hospitalized adults

Jason J. LeBlanc, May ElSherif, Sunita Mulpuru, Michelle Warhuus, A Ambrose et al. (35 authors)

Journal of Medical Microbiology2019-07-0210 citations

10.1099/jmm.0.001032

Effectiveness of Influenza Vaccination on Hospitalizations and Risk Factors for Severe Outcomes in Hospitalized Patients With COPD.

Mulpuru S, Li L, Ye L, Hatchette T, Andrew MK, Ambrose A, Boivin G, Bowie W, Chit A, Dos Santos G, ElSherif M, Green K, Haguinet F, Halperin SA, Ibarguchi B, Johnstone J, Katz K, Langley JM, LeBlanc J, Loeb M, MacKinnon-Cameron D, McCarthy A, McElhaney JE, McGeer A, Powis J, Richardson D, Semret M, Shinde V, Smyth D, Trottier S, Valiquette L, Webster D, McNeil SA, Serious Outcomes Surveillance (SOS) Network of the Canadian Immunization Research Network (CIRN).

2019-01-0171 citations

10.1016/j.chest.2018.10.044

The Impact of Prior Season Vaccination on Subsequent Influenza Vaccine Effectiveness to Prevent Influenza-related Hospitalizations Over 4 Influenza Seasons in Canada

Michaela Nichols, Melissa K. Andrew, L Ye, Todd F. Hatchette, A Ambrose et al. (28 authors)

Clinical Infectious Diseases2018-11-3022 citations

10.1093/cid/ciy1009

Influenza vaccine effectiveness to prevent influenza-related hospitalizations and serious outcomes in Canadian adults over the 2011/12 through 2013/14 influenza seasons: A pooled analysis from the Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS Network).

Nichols MK, Andrew MK, Hatchette TF, Ambrose A, Boivin G, Bowie W, Chit A, Dos Santos G, ElSherif M, Green K, Haguinet F, Halperin SA, Ibarguchi B, Johnstone J, Katz K, Lagacé-Wiens P, Langley JM, LeBlanc J, Loeb M, MacKinnon-Cameron D, McCarthy A, McElhaney JE, McGeer A, Poirier A, Powis J, Richardson D, Schuind A, Semret M, Shinde V, Smith S, Smyth D, Stiver G, Taylor G, Trottier S, Valiquette L, Webster D, Ye L, McNeil SA, Serious Outcomes Surveillance Network of the Canadian Immunization Research Network (CIRN), the Toronto Invasive Bacterial Diseases Network (TIBDN).

2018-03-1348 citations

10.1016/j.vaccine.2018.02.093

Influenza vaccine effectiveness against influenza-related hospitalization during a season with mixed outbreaks of four influenza viruses: a test-negative case-control study in adults in Canada.

Andrew MK, Shinde V, Hatchette T, Ambrose A, Boivin G, Bowie W, Chit A, Dos Santos G, ElSherif M, Green K, Haguinet F, Halperin SA, Ibarguchi B, Johnstone J, Katz K, Langley JM, LeBlanc J, Loeb M, MacKinnon-Cameron D, McCarthy A, McElhaney J, McGeer A, Nichols MK, Powis J, Richardson D, Semret M, Stiver G, Trottier S, Valiquette L, Webster D, Ye L, McNeil SA, Public Health Agency of Canada/Canadian Institutes of Health Research Influenza Research Network (PCIRN) Serious Outcomes Surveillance Network and the Toronto Invasive Bacterial Diseases Network (TIBDN).

2017-12-2920 citations

10.1186/s12879-017-2905-8

The Importance of Frailty in the Assessment of Influenza Vaccine Effectiveness Against Influenza-Related Hospitalization in Elderly People

Melissa K. Andrew, Vivek Shinde, Lingyun Ye, Todd F. Hatchette, François Haguinet et al. (31 authors)

The Journal of Infectious Diseases2017-06-10160 citations

10.1093/infdis/jix282

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

16 Years to No maximum

Healthy volunteers

No

Inclusion criteria

* Adult patients ≥ 16 years of age admitted to participating SOS Network hospitals with the following admitting diagnoses will be eligible for screening: * pneumonia * acute exacerbation of chronic obstructive pulmonary disease (AECOPD) or asthma * unexplained sepsis * Any other respiratory infection or diagnosis Or any respiratory or influenza-like symptom )(eg dyspnea, cough, sore throat, myalgia, arthralgia, fever, delirium/altered level of consciousness, CHF)

Exclusion criteria

* Patients whose reason for admission was clearly unrelated to the presence of influenza (for example, patients admitted due to trauma, elective surgery, or patients who have an alternative diagnosis that is clearly not respiratory,, e.g. cellulitis, intra-abdominal process, or gastrointestinal bleeding) Unless being enrolled as a nosocomial influenza case * Patients whose onset of symptoms was prior to or within 72 hours of hospital admission but who were not tested for influenza within 7 days of hospital admission. These should be captured on the screening form as screen failures. * No children in care will be enrolled in the study

Design outcomes

Primary

Measure	Time frame	Description
Estimate the burden of influenza disease and influenza vaccine effectiveness.	1 Year	Occurrence of any PCR-confirmed influenza virus infection in vaccinated (\>14 days after receipt of seasonal influenza vaccine) or unvaccinated adults ≥ 65 years of age.

Secondary

Measure	Time frame	Description
Estimate the burden of influenza disease and influenza vaccine effectiveness.	1 Year	Occurrence of any PCR-confirmed influenza virus infection in vaccinated (\>14 days after receipt of seasonal influenza vaccine) or unvaccinated adults ≥ 16 years of age

Countries

Canada

Outcome results